CMSC Consensus Statement on Neurofilament Biomarkers in Multiple Sclerosis
This consensus document was developed by an international panel of experts on neurofilament biomarker research and clinical applications in [...]
0
Guidance for the Use of Disease Modifying Therapies During the COVID-19 pandemic
People with MS have asked for guidance on the use of Disease Modifying Therapies (DMTs) during the COVID-19 pandemic. There are numerous [...]
2019 CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis
This guideline was developed by a group of multiple sclerosis (MS) specialists, convened by the Consortium of Multiple Sclerosis Centers [...]
A Survey of Risk Tolerance to Multiple Sclerosis Therapies
NARCOMS, the CMSC Patient Registry, is led by a team of world-renowned MS clinicians and researchers. Date from NARCOMS has provided the [...]
AAN Issues New Guideline on Complementary and Alternative Medicine in MS
According to a new AAN guideline, Complementary and Alternative Medicine in Multiple Sclerosis, there is little evidence for the [...]